The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Three Distinctly Different Kinds of Papillary Thyroid Microcarcinoma should be Recognized: Our Treatment Strategies and Outcomes
Abstract
Background: Papillary microcarcinoma (PMC) of the thyroid generally follows a benign clinical course. However, treatment strategies remain controversial. According to our previous retrospective review of 178 patients with PMC who underwent surgery between 1976 and 1993, the most significant risk factors affecting cancer‐specific survival were clinical symptoms at presentation due to invasion or metastasis. Distant metastasis and cancer‐specific death were never seen postoperatively for 148 cases (83%) of asymptomatic PMC without clinically apparent (≥1 cm) lymph node metastasis or recurrent nerve palsy. Based on these results, we identified three biologically different types of PMC that should be treated differently. Type I comprises incidentally detected PMC without any symptoms, which is harmless and the lowest‐risk cancer. Conservative follow‐up with ultrasonography every 6 or 12 months is feasible. Type II involves the early stage of the usual low‐risk papillary carcinoma. This can be treated by lobectomy when increasing size is noted during conservative follow‐up. Type III comprises clinically symptomatic PMC, representing a high‐risk cancer. Immediate wider resection followed by radioiodine treatment and suppression of thyroid‐stimulating hormone is recommended. Methods: Since 1995, we have been conducting a prospective clinical trial of nonsurgical observation for asymptomatic PMC. As of 2008, 230 of 244 candidates (94%) have decided to accept this policy, whereas 56 patients underwent surgery for symptomatic PMC between 1976 and 2006. Results: Nonsurgical observation for a mean of 5 (range, 1–17) years for 300 lesions of asymptomatic PMC revealed that 22 (7%) had increased in size, 269 (90%) were unchanged, and 9 (3%) had decreased. No patients developed extrathyroidal invasion or distant metastasis. Three patients (1%) who developed apparent lymph node metastasis and nine patients (4%) in whom tumor increased in size eventually received surgery after 1–12 years of follow‐up. No recurrences have been identified postoperatively. Conversely, 10‐year cause‐specific survival for symptomatic PMC was 80%. Multivariate analysis identified extrathyroidal invasion, large lymph node metastasis (≥2 cm), and poorly differentiated component as significantly related to adverse outcomes. Conclusions: Nonsurgical observation seems to represent an attractive alternative to surgery for asymptomatic PMC. Almost 95% of asymptomatic PMC patients are type I, and another 5% are type II and can be treated with conservative surgery. A small number of PMCs with bulky lymph node metastasis or extrathyroidal invasion are high‐risk type III and require aggressive treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,369
International Histological Classification of Tumours
Weller, R. (1981) · Journal of Clinical Pathology · doi:10.1136/jcp.34.6.692-d · Cited by 2,042
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Sherman, S. I., & Tuttle, R. M. (2006) · Thyroid · doi:10.1089/thy.2006.16.109 · Cited by 2,016
HAY, I. D., Bergstralh, E. J., Goellner, J. R., Ebersold, J. R., & Grant, C. S. (1993) · PubMed · Cited by 1,223
Papillary thyroid microcarcinoma: A study of 900 cases observed in a 60-year period
Hay, I. D., Hutchinson, M. E., Gonzalez-Losada, T., McIver, B., Reinalda, M. E., Grant, C. S., Thompson, G. B., Sebo, T. J., & Goellner, J. R. (2008) · Surgery · doi:10.1016/j.surg.2008.08.035 · Cited by 940
An expanded view of risk-group definition in differentiated thyroid carcinoma.
Cady, B., & Rossi, R. (1988) · PubMed · Cited by 937
Ito, Y., Uruno, T., Nakano, K., Takamura, Y., Miya, A., Kobayashi, K., Yokozawa, T., Matsuzuka, F., Kuma, S., Kuma, K., et al. (2003) · Thyroid · doi:10.1089/105072503321669875 · Cited by 877
Wada, N., Duh, Q.-Y., Sugino, K., Iwasaki, H., Kameyama, K., Mimura, T., Ito, K., Takami, H., & Takanashi, Y. (2003) · Annals of Surgery · doi:10.1097/01.sla.0000055273.58908.19 · Cited by 815
HAY, I. D., Grant, C. S., Taylor, W. F., & McConahey, W. M. (1987) · PubMed · Cited by 764
Chow, S., Law, S. C. K., Chan, J. K. C., Au, S., Yau, S., & Lau, W. (2003) · Cancer · doi:10.1002/cncr.11442 · Cited by 723
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Cabanillas, M. E., McFadden, D. G., & Durante, C. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30172-6 · Cited by 1,430
Guidelines for the management of thyroid cancer
Perros, P., Boelaert, K., Colley, S., Evans, C., Evans, R. M., Gerrard BA, G., Gilbert, J., Harrison, B., Johnson, S. J., Giles, T. E., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12515 · Cited by 1,372
The changing incidence of thyroid cancer
Kitahara, C. M., & Sosa, J. A. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.110 · Cited by 1,051
Metadata
- Authors
- Sugitani, I., Toda, K., Yamada, K., Yamamoto, N., Ikenaga, M., & Fujimoto, Y.
- Venue
- World Journal of Surgery
- Publisher
- Wiley
- Published
- 2010-01-12
- Volume
- 34
- Issue
- 6
- Pages
- 1222-1231
- ISSN
- 0364-2313 (ISSN-L)
- 1432-2323
- OpenAlex
- W1979091043
- Cited by
- 519
- References
- 33
- FWCI
- 10.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Three Distinctly Different Kinds of Papillary Thyroid Microcarcinoma should be Recognized: Our Treatment Strategies and Outcomes. https://app.cochat.ai/papers/10.1007/s00268-009-0359-x
- The paper
- Sugitani, I., Toda, K., Yamada, K., Yamamoto, N., Ikenaga, M., & Fujimoto, Y. (2010). Three Distinctly Different Kinds of Papillary Thyroid Microcarcinoma should be Recognized: Our Treatment Strategies and Outcomes. World Journal of Surgery. https://doi.org/10.1007/s00268-009-0359-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.